Fresenius SE & Co KGaA
XETRA:FRE

Watchlist Manager
Fresenius SE & Co KGaA Logo
Fresenius SE & Co KGaA
XETRA:FRE
Watchlist
Price: 33.31 EUR 1.59% Market Closed
Market Cap: 18.8B EUR
Have any thoughts about
Fresenius SE & Co KGaA?
Write Note

Gross Margin
Fresenius SE & Co KGaA

24%
Current
25%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
24%
=
Gross Profit
5.3B
/
Revenue
21.9B

Gross Margin Across Competitors

Country DE
Market Cap 18.8B EUR
Gross Margin
24%
Country US
Market Cap 91.8B USD
Gross Margin
11%
Country US
Market Cap 87.7B EUR
Gross Margin
11%
Country US
Market Cap 73B USD
Gross Margin
14%
Country DE
Market Cap 24.9B EUR
Gross Margin
25%
Country US
Market Cap 20.1B USD
Gross Margin
28%
Country US
Market Cap 18.3B USD
Gross Margin
33%
Country US
Market Cap 13.7B USD
Gross Margin
33%
Country DE
Market Cap 12.4B EUR
Gross Margin
25%
Country AU
Market Cap 13.4B AUD
Gross Margin
84%
Country US
Market Cap 8.6B USD
Gross Margin
36%
No Stocks Found

Fresenius SE & Co KGaA
Glance View

Market Cap
18.8B EUR
Industry
Health Care

Fresenius SE & Co KGaA is a global healthcare group rooted in Germany, dedicated to providing high-quality medical services and products to patients worldwide. Founded in 1912, the company has grown into a diverse organization with a strong focus on life-saving therapies in renal care, hospital services, and pharmaceutical manufacturing. With its subgroups—Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed—the company operates across different segments that collectively support its vision of enhancing patient outcomes, improving quality of care, and meeting the increasing demand for healthcare services in an aging global population. By leveraging an extensive network of healthcare facilities, innovative product pipelines, and a commitment to sustainability, Fresenius positions itself as a leader in the dynamic healthcare landscape. For investors, Fresenius SE & Co KGaA represents an opportunity to engage with a stable yet growth-oriented enterprise. The company has consistently demonstrated resilience, even amidst market fluctuations, reflecting a strong financial foundation and strategic leadership. With the global healthcare market projected to expand, driven by an increase in chronic diseases and the need for advanced medical solutions, Fresenius is well-poised to capture significant market share. Its focus on innovation, particularly in personalized medicine and digital health, underscores a forward-thinking approach that aligns with evolving patient needs. As a long-term investment option, Fresenius' commitment to enhancing healthcare accessibility and efficiency not only offers the potential for financial returns but also contributes positively to global health outcomes, making it a compelling choice for investors looking for a balance of impact and profit.

FRE Intrinsic Value
70.19 EUR
Undervaluation 53%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
24%
=
Gross Profit
5.3B
/
Revenue
21.9B
What is the Gross Margin of Fresenius SE & Co KGaA?

Based on Fresenius SE & Co KGaA's most recent financial statements, the company has Gross Margin of 24%.